This probability was further increased in patients presented with double mutations of BARD1 Cys557Ser joint with XRCC3 241Met variant (P = 0.02, OR = 5.01 [95% CI 1.36–18.5]) among patients with a family history of breast or/an ovarian cancer [56]. Here, BARD1 is linked to ovarian cancer.